CNSO Stock UPDATES Cns Response Inc. (CNSO) 0.2500 09/10/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cns Response Inc. (CNSO) 0.2500 $CNSO

RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Tue Sep 09, 1:34PM CDT
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature three companies on Fox Business nationwide on Tuesday, September 9 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg Europe on Sunday, September 14 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, September 14 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday September 14 at 3:30 p.m. HKT.

CNS Response Showcases PEER at AdvaMed Capitol Hill Event
GlobeNewswire - Mon Jun 16, 4:08PM CDT
CNS Response, Inc. (OTCBB:CNSO):

New Pacific Reports Financial Results for the Three and Six Months Ended December 31, 2013-Appoints President and Senior Vice-President
Marketwire Canada - Wed Feb 12, 4:05PM CST
New Pacific Metals Corp. ("New Pacific" or the "Company" (TSX:NUX) today announced its unaudited condensed consolidated interim financial results for the three and six months ended December 31, 2013.

New Study Says Just 5% of Mental Health Patients Receive Objective Test Before Getting Prescription Drugs
GlobeNewswire - Thu Dec 19, 10:41AM CST
96% of Patients Expect Doctor to Have Objective Information

CNS Response Inc concludes USD2m in private placement
M2 - Tue Sep 17, 8:55AM CDT
Web neuroinformatic company CNS Response Inc (Other OTC:CNSO) revealed on Monday the the completion of a USD2m in a private placement of common stock.

CNS Response Completes $2 Million Financing
GlobeNewswire - Mon Sep 16, 5:39PM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced the completion of a private placement of $2 million from the sale of common stock at $.25 per share, resulting in the issuance of 8 million shares of common stock. Of the shares sold, 3,850,000 were purchased by Directors, Officers and affiliate shareholders of the Company. The remaining 4,150,000 shares were acquired by new investors and repeat investors, in each case qualified to participate in private placements pursuant to SEC rules.

Cloud Computing, E-Waste and More Hot Micro-Cap Stock Sectors
Marketwire - Mon Aug 26, 8:01AM CDT
CNS Response, Inc. (OTCQB: CNSO) provides reference data and analytic tools for clinicians and researchers in psychiatry. Treatment for mental disorders has doubled in the last 20 years and use of psychotropic medications has grown over 400% -- but treatments fail more often than they succeed and over 17 million Americans have failed two or more medication therapies for their mental disorder. Read about the company's recent debt restructuring and innovative treatment approach at this link: http://bit.ly/RESEARCHCNSO

CNS Response Announces 100% Note Conversion
GlobeNewswire - Mon Aug 19, 8:30AM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced that all 25 of its note holders who have held convertible notes issued between October 2010 and February 2012 have agreed to convert $7.8 million of principal and interest into common stock. This conversion substantially reduces the Company's debt outstanding, simplifies the Company's capital structure and greatly improves the Company's working capital position.

CNS Response Announces Four New Patents
GlobeNewswire - Wed May 15, 3:30PM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced that it has received four additional patents for its PEER Interactive technology. Two of the patents -- one in the US and one in Japan -- relate to the Company's method of classifying individual patients based on their unique Quantitative EEG (QEEG) responsivity profile. The third patent, issuing in Canada, relates to the Company's method of determining medication efficacy by comparing QEEG data measured before and after medication administration. The fourth patent, issuing in Japan, relates to the Company's method of recommending therapy based upon an individual's unique QEEG responsivity profile.

CNS Response Expands Its Technology to Fort Belvoir
GlobeNewswire - Fri May 10, 9:00AM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced that it has opened a second site for its PEER Interactive trial at Fort Belvoir Community Hospital in Virginia, one of the Army's largest treatment facilities for active military personnel. Fort Belvoir is the second military site to participate under an approved, 2,000-soldier protocol and Cooperative Research and Development Agreement.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Promising Interim Findings from Medicus Pharma's BCC Study

Updated Category News Views 164

Positive Interim Analysis from Medicus Pharma Ltd Medicus Pharma Ltd. (NASDAQ: MDCX) has recently shared exciting interim results from its SKNJCT-003 Phase 2 clinical study, which focuses on a non-invasive approach to treat basal cell carcinoma (BCC) of the skin. This news marks a significant milestone as the company aims to revolutionize the treatment options available...

Continue Reading
DroneShield's Immediate Response Kit Wins Platinum Award for Innovation

Updated Category News Views 161

DroneShield's Immediate Response Kit Gains Recognition for Innovation DroneShield has recently been awarded the prestigious Platinum Award for Innovation by Military and Aerospace Electronics, showcasing its Immediate Response Kit (IRK) as a cornerstone in drone detection and defeat technology. This award is a testament to the exceptional capabilities of the IRK, which...

Continue Reading
Jefferies Holds ABB Rating; Analysts Assess Mixed Results

Updated Category News Views 65

Jefferies Maintains Hold Rating on ABB Stock Jefferies recently continued its Hold rating for ABB Ltd (NYSE: ABB) and set a price target of CHF50.00, following the company's third-quarter performance report. The report showcased a mixed array of results, with certain metrics outperforming expectations while others showed disappointing trends. During the third quarter, ABB...

Continue Reading
Surgical Clips Market Projected to Reach $1.8 Billion Soon

Updated Category News Views 211

Overview of the Surgical Clips Market Recent analysis of the surgical clips market reveals an impressive valuation of USD 655.9 million in 2023, with projections indicating a potential growth to USD 1.8 billion by 2032. This remarkable increase is attributed to a compound annual growth rate (CAGR) of 11.9% from 2024. Understanding Surgical Clips and Their Importance...

Continue Reading
Public Disclosure of Opening Position by Keywords Studios Plc

Updated Category News Views 74

Public Opening Position Disclosure for Keywords Studios Plc This document provides important information about a public opening position disclosure related to Keywords Studios Plc. It includes details about individuals or entities holding 1% or more of relevant securities. This disclosure is made in accordance with Rule 8.3 of the Takeover Code, which ensures that all...

Continue Reading